LUND, Sweden, June 24, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China...
from PR Newswire: https://ift.tt/3vQnCu0
No comments:
Post a Comment